Allergy Therapeutics (AGY) Competitors GBX 8.30 +0.30 (+3.75%) As of 11:58 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock AGY vs. AMYT, APH, ANCR, VLG, EAH, DNL, STX, PXS, CHLL, and MXCShould you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), ECO Animal Health Group (EAH), Diurnal Group (DNL), Shield Therapeutics (STX), Provexis (PXS), Chill Brands Group (CHLL), and Argent BioPharma (MXC). These companies are all part of the "drug manufacturers - specialty & generic" industry. Allergy Therapeutics vs. Its Competitors Amryt Pharma Alliance Pharma Animalcare Group Venture Life Group ECO Animal Health Group Diurnal Group Shield Therapeutics Provexis Chill Brands Group Argent BioPharma Amryt Pharma (LON:AMYT) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Is AMYT or AGY more profitable? Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -72.86%. Amryt Pharma's return on equity of 0.00% beat Allergy Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amryt PharmaN/A N/A N/A Allergy Therapeutics -72.86%-266.59%-34.76% Which has stronger valuation and earnings, AMYT or AGY? Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmryt Pharma£210.24M0.00N/A-£33.00N/AAllergy Therapeutics£72.18M5.65-£52.59M-£1.04-8.00 Does the media favor AMYT or AGY? In the previous week, Allergy Therapeutics had 2 more articles in the media than Amryt Pharma. MarketBeat recorded 2 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Amryt Pharma's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score. Company Overall Sentiment Amryt Pharma Neutral Allergy Therapeutics Neutral SummaryAmryt Pharma beats Allergy Therapeutics on 5 of the 7 factors compared between the two stocks. Get Allergy Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGY vs. The Competition Export to ExcelMetricAllergy TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£407.95M£2.17B£5.54B£3.02BDividend Yield8.33%2.92%3.75%5.02%P/E Ratio-8.004.2421.01165.88Price / Sales5.65582.79433.81285,131.44Price / Cash3.6610.3536.1627.97Price / Book84.1111.338.124.46Net Income-£52.59M£21.15B£3.25B£5.90B7 Day Performance0.61%1.25%0.97%3.82%1 Month Performance18.57%6.17%7.36%9.81%1 Year Performance50.91%3.88%31.31%74.29% Allergy Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGYAllergy TherapeuticsN/AGBX 8.30+3.8%N/A+51.5%£407.95M£72.18M-8.00612AMYTAmryt PharmaN/AN/AN/AN/A£457.11M£210.24M-4.33290Gap DownAPHAlliance Pharma2.0338 of 5 starsGBX 64.70flatGBX 6,250+9,560.0%N/A£350.32M£183.50M-10.4391,000ANCRAnimalcare GroupN/AGBX 280+0.7%N/A+19.1%£191.97M£84.90M5.22220VLGVenture Life GroupN/AGBX 56-1.8%N/A+13.4%£71.36M£51.77M95.03165EAHECO Animal Health Group3.5189 of 5 starsGBX 73.40-4.1%GBX 150+104.4%-36.8%£49.74M£89.44M47.45234News CoverageEarnings ReportInsider TradeGap DownHigh Trading VolumeDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133STXShield TherapeuticsN/AGBX 3.43-5.9%N/A+114.6%£33.88M£20.92M-0.8840,000PXSProvexisN/AGBX 0.72-7.6%N/A+21.4%£16.80M£846.98K-27.144Gap DownCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624.19K-215.007Earnings ReportMXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap Up Related Companies and Tools Related Companies AMYT Competitors APH Competitors ANCR Competitors VLG Competitors EAH Competitors DNL Competitors STX Competitors PXS Competitors CHLL Competitors MXC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AGY) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGY Stock Alerts